Top News: Crinetics raises $63.5 million in new funds and adds to BOD

In the News

Crinetics has completed a $63.5 million Series B financing to continue development of its lead product for acromegaly and other new therapeutics targeting rare endocrine disorders. This funding was led by Perceptive Advisors, a New York biotech fund, and was joined by two other new investors, RA Capital and OrbiMed.  The financing round also included…

read more

The San Diego Union-Tribune: Crinetics raises $40 million

In the News

November 2, 2015 — Seeking to get its first drug ready for human testing, San Diego biotech Crinetics Pharmaceuticals has raised $40 million in venture capital funding. Crinetics is developing a drug to treat acromegaly, a rare endocrine disorder caused by overproduction of human growth hormone in adults. It can raise the risk of several diseases,…

read more